Brokerages Set Mural Oncology PLC (NASDAQ:MURA) PT at $12.00

Shares of Mural Oncology PLC (NASDAQ:MURA) have earned an average recommendation of “Hold” from the five analysts that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $12.00.

Several brokerages have recently issued reports on MURA. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Mural Oncology in a research report on Wednesday, October 8th. Wall Street Zen downgraded Mural Oncology from a “hold” rating to a “strong sell” rating in a research report on Sunday, August 10th.

Mural Oncology Stock Performance

Shares of NASDAQ:MURA opened at $2.10 on Tuesday. The company has a market cap of $36.39 million, a P/E ratio of -0.24 and a beta of 2.93. The stock’s 50-day moving average is $2.08 and its 200-day moving average is $2.30. Mural Oncology has a 52-week low of $0.95 and a 52-week high of $4.74.

Mural Oncology (NASDAQ:MURA) last issued its quarterly earnings results on Monday, August 4th. The company reported ($1.77) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.13) by ($0.64). As a group, equities analysts predict that Mural Oncology will post -7.54 EPS for the current year.

Institutional Investors Weigh In On Mural Oncology

A number of institutional investors have recently added to or reduced their stakes in MURA. Soleus Capital Management L.P. acquired a new stake in Mural Oncology during the second quarter worth about $3,270,000. Orbimed Advisors LLC bought a new position in Mural Oncology during the second quarter worth about $1,454,000. LMR Partners LLP bought a new position in Mural Oncology during the second quarter worth about $1,276,000. Diametric Capital LP bought a new position in Mural Oncology during the second quarter worth about $864,000. Finally, Deltec Asset Management LLC bought a new position in Mural Oncology during the third quarter worth about $371,000. 80.21% of the stock is owned by institutional investors and hedge funds.

Mural Oncology Company Profile

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.